1639137-80-6

Basic information

• Product Name: N-methyl-2-((1-acetyl-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide
• Synonyms: N-methyl-2-((1-acetyl-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide
• CAS NO: 1639137-80-6
• Molecular Weight: 428.514
• Mol File: 1639137-80-6.mol
• Article Data: 3

Chemical Properties

• Melting Point: 214 - 215°C
• Density: 1.27±0.1 g/cm3(Predicted)
• CAS DataBase Reference: N-methyl-2-((1-acetyl-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-methyl-2-((1-acetyl-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide(1639137-80-6)
• EPA Substance Registry System: N-methyl-2-((1-acetyl-3-((1E)-2-(2-pyridinyl)ethenyl)-1H-indazol-6-yl)thio)benzamide(1639137-80-6)

Safety Data

• Hazardous Substances Data: 1639137-80-6(Hazardous Substances Data)

Usage

Uses

N-Acetyl Axitinib is an intermediate used in the synthesis of Axitinib. Axitinib is a tyrosine kinase inhibitor that is also used in cancer therapy.

Upstream product

• 319460-85-0 axitinib 
• 75-36-5 acetyl chloride 
• 20054-45-9 N-methyl-2-sulfanylbenzamide 
• 100-69-6 2-vinylpyridine 
• 1639138-00-3 axitinib 
• 885126-34-1 2-((3-iodo-1H-indazol-6-yl)thio)-N-methylbenzamide 
• 944835-85-2 2-{(1H-indazol-6-yl)thio}-N-methylbenzamide 
• 261953-36-0 6-Iodo-1H-indazole 

Downstream Products

• 319460-85-0 axitinib 

Relevant articles and documents

Prodrug compound and application ofprodrug compound in treatment of cancer

The present invention provides a compound indicated by a formula (I), pharmaceutically acceptable salts or esters thereof, a pharmaceutical composition of the compound, and application of the compoundand the pharmaceutical composition in the inhibition or regulation of the activity of tyrosine kinase and treating disease symptoms or symptoms including cancer mediated by tyrosine kinase.

Development of an efficient Pd-catalyzed coupling process for axitinib

The manufacturing process of axitinib (1) involves two Pd-catalyzed coupling reactions, a Migita coupling and a Heck reaction. Optimization of both of these pivotal bond-formation steps is discussed as well as the approach to control impurities in axitinib. Essential to the control strategy was the optimization of the Heck reaction to minimize formation of impurities, in addition to the development of an efficient isolation of crude axitinib to purge impurities.